|1.||Zalutsky, Michael R: 7 articles (01/2012 - 03/2003)|
|2.||Vaidyanathan, Ganesan: 5 articles (08/2009 - 03/2003)|
|3.||Bigner, Darell D: 3 articles (01/2012 - 05/2003)|
|4.||Boskovitz, Abraham: 2 articles (01/2012 - 04/2004)|
|5.||Pegram, Charles N: 2 articles (01/2012 - 04/2004)|
|6.||Shankar, Sriram: 2 articles (10/2004 - 03/2003)|
|7.||Affleck, Donna J: 2 articles (10/2004 - 05/2003)|
|8.||Talavera, Karel: 1 article (08/2013)|
|9.||Ni, Yicheng: 1 article (08/2013)|
|10.||Sun, Ziping: 1 article (08/2013)|
08/01/2012 - "In the present study, BLMG was primarily enzymatically synthesized by using a microsome preparate separated from rat liver, labeled with (131)I by iodogen method with the aim of generating a radionuclide-labeled prodrug, and investigated its bioaffinities with tumor-bearing Balb/C mice. "
01/01/2013 - "In vitro stability, specificity, and affinity of radioiodinated chAb and fragments (Iodo-Gen method) were examined on high-expressing αvβ5 A549 lung tumor cells. "
10/01/2004 - "Tumor uptake of [131I]SIPMB-L8A4 (41.9+/-3.5% ID/g) was nearly threefold that of L8A4 labeled using Iodogen (14.0+/-1.1% ID/g) after 2 days, and tumor to tissue ratios remained uniformly high throughout with [131I]SIPMB-L8A4. "
03/01/2001 - "For this labeling, 5 mg MAb were coated with 35 microg IODO-GEN during 3 min in a reaction volume of 6 mL. Also, biodistribution was optimal, and tumor accumulation was superior to that of coinjected (125)I-c-MOv18 labeled according to the conventional IODO-GEN-coated vial method. "
08/01/1997 - "Radioiodination with the Iodogen method led to impaired immunoreactivity which was found to further increase the off- rates of radioiodinated fragments from tumor cells. "
03/01/2003 - "Internalization and processing in the U87DeltaEGFR glioma cell line was studied in a paired label format with L8A4 labeled with (125)I using the Iodogen method. "
04/01/2004 - "In the current study, a series of paired-label experiments were performed in athymic mice bearing subcutaneous D-245 MG human glioma xenografts to compare the biodistribution of the fragment ch81C6 F(ab')(2) labeled using Iodogen to a) intact ch81C6, b) mu81C6, and c) ch81C6 F(ab')(2) labeled using N-succinimidyl 3-[(131)I]iodobenzoate. "
10/01/2004 - "Biodistribution experiments in athymic mice bearing subcutaneous D-256 human glioma xenografts were performed to compare L8A4 labeled using [131I]SIPMB to L8A4 labeled with 125I using both the analogous positively charged acylation agent N-succinimidyl-4-guanidinomethyl-3-[125I]iodobenzoate ([125I]SGMIB) and Iodogen. "
02/01/2009 - "Paired-label internalization and cellular processing assays were performed on EGFRvIII-expressing U87.DeltaEGFR glioma cells over 24 h to directly compare (177)Lu-labeled L8A4 to L8A4 labeled with (125)I using either iodogen or N-succinimidyl 4-guanidinomethyl-3-[(125)I]iodobenzoate ([(125)I]SGMIB). "
05/01/1996 - "When labeled using the Iodogen method, a chimeric antibody composed of the human IgG2 constant region and the variable regions of murine anti-tenascin 81C6 exhibited superior uptake in human glioma xenografts compared with its murine parent. "
03/01/1989 - "NCC-ST-433 monoclonal antibody raised against human gastric carcinoma xenograft (St-4) was labeled with 125I using enzymatic and Iodogen methods. "
07/01/1989 - "Fourteen patients with carcinoma of the breast proved at biopsy received Mab B72.3 (5 millicuries of 125I per 1 milligram, Iodo-Gen method) intravenously six to 26 days before exploration. "
01/01/1985 - "A monoclonal antibody (B6.2) directed against human breast carcinomas and its F(ab')2 and Fab' fragments were labeled with 125I using Iodogen. "
03/01/1990 - "HMD4, a human IgG (lambda) monoclonal antibody against ovarian carcinoma, was purified by affinity chromatography of CNBr-activated Sepharose 4 B coupled with goat antihuman IgG, 131I-HMD4 was prepared by chloramin-T or Iodogen method. "
|4.||Breast Neoplasms (Breast Cancer)
08/01/2009 - "Paired-label internalization assays of the labeled fragments were performed in vitro using MCF7 human breast cancer cells transfected to express HER2 (MCF7-HER2); comparisons were made to scFv-Fc DM directly radioiodinated using Iodogen. "
07/01/1991 - "The combined use of the iodogen and the two-dimensional gel electrophoresis methods has allowed us to demonstrate the presence of cytokeratins 8, 18 and 19 on the outer surface of established human mammary carcinoma cells, in particular MCF-7 cells, while they were absent from the surface of normal mammary cells in primary culture. "
12/01/1995 - "Radioimmunotherapy experiments in athymic mice bearing established MDA MB 361 human breast cancer xenografts showed growth inhibition for > 24 days at a dose of 600 microCi/mouse (P < 0.0001) when labeled by the IodoGen technique, and 12 days using the MATE method (P < 0.0001)."
01/01/1988 - "Binding to the breast cancer cell line, MCF-7, of native MAb DF3 was compared to that of MAb DF3 exposed to different concentrations of Iodogen or Bolton-Hunter reagent. "
12/01/1995 - "Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate radioiodination methods."
|5.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
|1.||N- succinimidyl- 5- iodo- 3- pyridinecarboxylic acid
|2.||epidermal growth factor receptor VIII
|7.||Immunoglobulin G (IgG)
|1.||Heterologous Transplantation (Xenotransplantation)
|4.||Drug Therapy (Chemotherapy)